AAAdil Al-Nahhas

Adil Al-Nahhas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adil Al-Nahhas has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multivisceral transplantation and vascularised sentinel forearm flap for a metastatic small bowel neuroendocrine tumour: Update on follow-up

    by A Frilling, H Giele, G Vrakas, S Reddy, R Macedo, A Al-Nahhas, H Wasan, Ak Clift, Ge Gondolesi, Rm Vianna, et al.

    Introduction: We previously reported the first documented case of a novel approach in a patient with extensive mesenteric metastases from a small bowel (SB) NET: this combined multivisceral transplantation (MVT) and a vascularised sentinel forearm flap (VSFF) from the same donor. Aim(s): We re-present this case after 38-month follow-up post-MVT/VSFF. Materials and methods: A 44-year old male patient was diagnosed with a well-differentiated, grade 1 (Ki67 <1%) neuroendocrine tumour. Initial gut hormones were raised: chromogranin A 395 pmol/l (normal <60), chromogranin B 349 pmol/l (normal <150) and 24 hr urinary 5-HIAA 643 μmol/l (normal <40). Pre-operative 68-Ga DOTATATE PET/CT showed uptake in an aorto-caval lymph node and bulky mesenteric disease, which was confirmed at laparotomy as stage IV disease encasing the mesenteric root. Numerous lymph nodes and multifocal primary tumour (7 sub-centimetre lesions) were also found at surgery. Results: 4 cycles of neoadjuvant 177-Lu PRRT were followed by modified MVT (stomach, pancreas, spleen, small bowel, right hemi-colon), VSFF and resection of the aorto-caval lymph node. Disease stage was pT3 N1 M0 L1 V0 R0. Conclusion: 38 months post-MVT/VSFF the patient is well and fully physically active with no evidence of disease recurrence on follow-up imaging or biochemistry. There was never any rejection in the visceral graft, with one mild, easily treated reaction in the VSFF. (Work published). Keywords: neuroendocrine, transplantation, multivisceral, forearm flap

    • 1 December 2011
      • Vol. 59  (6) , 533-42

    In high risk hypertensive subjects with incidental and unilateral renal artery stenosis percutaneous revascularization with stent improves blood pressure control but not glomerular filtration rate.

    by A Mazza, G Rigatelli, M Piva, L Rampin, P Cardaioli, M Giordan, L Roncon, L Zattoni, M Zuin, A Al-Nahhas, et al.

    In high-risk hypertensive subjects (HTs) with incidental unilateral renal artery stenosis (RAS), the effectiveness of percutaneous revascularization with stent (PR-STENT) on blood pressure (BP) and glomerular filtration rate (GFR) is not established. Eighteen HTs aged 65.7 ± 9.2 years with angiographically diagnosed unilateral RAS (≥ 60%) were randomized to receive PR-STENT (N=9) or to NO-STENT (N=9). BP (mercury sphygmomanometer) and GFR (99mTc-DTPA clearances during renal scintigraphy) were evaluated yearly for three years. Echo-Doppler of renal arteries was performed to verify the anatomic patency and flow velocities of the reperfused artery. Analysis of variance compared BP and GFR values changes from baseline to the follow-up; differences for continuous variables were evaluated between groups with the Tukey's post hoc test after adjustment for age, change of BP between baseline and at the follow-up, GFR and body mass index (BMI). Baseline systolic BP and GFR values were not different between groups. The significantly greater GFR increase observed in PR-STENT than in NO-STENT at univariate analysis at the end of follow-up (62.5 ± 19.2 vs. 42.24 ± 17.6, P<0.02) disappeared after adjustment for confounding factors. However, systolic BP remained significantly lower in PR-STENT than in NO-STENT (140.1 ± 4.6 vs. 170.0 ± 8.3, P<0.0001) also after adjustment for age, GFR and BMI. PR-STENT reduces systolic BP without improving GFR. Due to the strong association between high BP and renal damage, this study raises the question on whether PR-STENT should be performed in all HTs with unilateral and incidental RAS.


    • 19 October 2010
      • Vol. 24  (5) , 771-4

    Diagnostics of neuroendocrine tumours.

    by M Hodolic, J Fettich, E Banti, S Chondrogiannis, A Al-Nahhas, D Rubello

    Neuroendocrine tumours (NETs) are rare pathologies which origin from neuroectodermic and endodermic cells and that can produce peptides and amino acids. About 70% of NETs derive from gastroenterohepatic (GEP) system and the other 30% from the different sites through the body. They are distinguished into single and multiple localizations and also into sporadic, familial multiple endocrine-related forms and recurrent forms. Moreover, when they produce hormones they usually are symptomatic; yet, they are characterized by the synthesis and secretion in the blood stream of several tumor-specific markers or can express somatostatin receptors in their cellular surface. The diagnosis and follow-up of NETs rely on laboratory studies, histopathology and the combination of anatomical and functional imaging, with the latter being the main method for monitoring response to therapy. In recent years, nuclear medicine has contributed to the impressive development of the knowledge of NETs in terms of biology (receptor scintigraphy), pharmacology (development of new tracers) and therapy (radiometabolic therapy). Nuclear medicine procedures for diagnosis and treatment of NETs are based on the biological properties of these tumours: the expression of somatostatin receptors. Somatostatin receptor scintigraphy not only has a crucial role in diagnosis and staging of NETs, but also in assessing suitability for treatment with cold and radiolabelled somatostatin analogues, as well as in monitoring response to treatment and detecting recurrent disease. In conventional nuclear medicine, the two most important functional imaging modalities are ¹¹¹In-octrescan and ¹²³I-MIBG. Over the last 5 years, due to the development of new tracers, such as ⁶⁸Ga labelled-DOTA-peptides PET and ¹⁸F-DOPA, PET has also been employed with significant benefits in the diagnosis and management of NETs.


    • 1 March 2010
      • Vol. 35  (1) , 17-25

    Functional assessment in the multimodality imaging of pancreatic neuro-endocrine tumours.

    by K Bhate, W Y Mok, K Tran, S Khan, A Al-Nahhas

    Pancreatic neuroendocrine tumours comprise a heterogeneous group that are rare but could result in serious manifestations. Surgical excision provides the best approach to treatment but many patients may have small lesions that are difficult to detect, or present with wide spread disease by the time of diagnosis. In addition to clinical assessment and biochemical tests, imaging is a major factor in establishing the diagnosis. Cross-sectional imaging such as US, CT and MR, play a major role in the initial assessment. However, they may miss small lesions or metastatic spread. Functional Imaging became possible with the development of somatostatin receptor imaging using 111In-octreotide, which when combined with anatomical imaging could provide enhanced detection. A major improvement has been achieved by combining receptor and PET inaging through the use of 68Ga-DOTA complexes that have been shown to have a much better sensitivity than other imaging modalities and can provide the basis for radionuclide treatment with 90Y or 177Lu labelled with DOTA complexes.


    • 1 September 2009
      • Vol. 34  (3) , 223-36

    Multiorgan dysfunctions in diabetic patients: the role of functional imaging.

    by S Shah, Z Win, A Al-Nahhas

    Functional imaging plays a central role in the evaluation of some of the clinical problems faced by diabetic patients. In cardiovascular disease, myocardial perfusion imaging, particularly when complemented by gated SPECT, is a powerful tool not only for establishing the diagnosis of coronary artery disease, but also for providing prognostic information in both the general and diabetic populations. Although promising, its role in screening of asymptomatic diabetic patients is yet to be established, and its role as a potential 'one-stop shop' also needs further study. PET is currently the gold standard for viability assessment, and also provides prognostic data, but its widespread use is limited by cost and availability. Hybrid imaging with PET/CT is promising, and could revolutionise cardiac imaging by combining functional and anatomic information. In the investigation of the diabetic foot, labelled leukocyte imaging is the nuclear medicine test of choice to diagnose osteomyelitis. It is likely that SPECT/CT will further improve diagnostic accuracy, but more studies are needed. Combined leukocyte and bone marrow imaging is of value in distinguishing osteomyelitis from neuropathic osteoarthropathy in the diabetic foot; PET and PET/CT may also be of value in these cases, but their wider role is currently inconclusive. The value of bone scintigraphy in the diabetic foot, even as a screening test, is questionable. Functional imaging methods can also be employed in the evaluation of other diabetic complications, including the assessment of left ventricular function, renal scarring and gastric emptying, but these methods are not widely used in current clinical practice.


    • 1 September 2008
      • Vol. 33  (3) , 193-202

    Multimodality imaging of the parathyroid glands in primary hyperparathyroidism.

    by S Shah, Z Win, A Al-Nahhas

    Primary hyperparathyroidism is a common endocrine disorder, affecting approximately 1 in 500 women and 1 in 2,000 men. Surgical removal of the hyperfunctioning parathyroid gland is the primary curative treatment. The last decade has witnessed the development of minimally invasive parathyroidectomy, which is based on the fact that the vast majority of cases are caused by single adenomas. However, the success of this technique relies on accurate preoperative localisation of the parathyroid lesions. The imaging modalities used vary at different institutions according to local expertise and availability, but include high resolution ultrasound, radionuclide studies, computed tomography (CT) and magnetic resonance imaging (MRI). Ultrasound and 99mTc sestamibi scintigraphy, particularly when complemented by single photon emission computed tomography (SPECT), are currently the imaging techniques of choice for preoperative localisation of parathyroid adenomas; a combination of the two methods further improves the sensitivity and accuracy of detection. CT is less commonly used for preoperative localisation and usually reserved for cases of failed parathyroidectomy, for the detection of suspected ectopic glands. MRI appears to be useful in patients with persistent or recurrent hyperparathyroidism, who have previously undergone surgery. Cross-sectional imaging is also useful in cases where the findings at sonography and scintigraphy are discordant. SPECT/CT appears promising, but further studies are needed to evaluate its role in preoperative localisation.


    • 1 June 2008
      • Vol. 33  (2) , 41-52

    PET imaging in endocrine tumours.

    by S Khan, C Lloyd, T Szyszko, Z Win, D Rubello, A Al-Nahhas

    The role of PET in the assessment of endocrine tumours has been, until recently, restricted to the use of (18)F-fluoro-deoxy-D-glucose ((18)F-FDG). Being a marker of metabolically active lesions that show high grading and low differentiation, FDG is not ideal for this purpose since the majority of endocrine tumours are slow growing and highly differentiated. It is however useful when dedifferentiation takes place and provides excellent prognostic information. A number of hormone precursors and amino acids are labelled with (11)C and used successfully in the management of parathyroid, adrenal and pituitary tumours. However, the short half-life of (11)C radiopharmaceuticals restricts their use to centres with access to an on-site cyclotron, while the high cost of production may limit their use to research purposes. A promising new positron-emission tomography (PET) tracer is Gallium-68 obtained by elution from a long shelf-life generator that makes it economic and cyclotron-independent. Its short half-life and flexible labelling ability to a wide range of peptides and antibodies makes it ideal for PET imaging. In addition to imaging GEP-NETs and phaeochromocytoma, it has the potential to be used in a wider range of endocrine tumours.


    • 10 April 2008
      • Vol. 22  (1) , 109-14

    Review. 18F-FDG PET in the diagnosis and follow-up of thyroid malignancy.

    by A Al-Nahhas, S Khan, A Gogbashian, E Banti, L Rampin, D Rubello

    The diagnosis of carcinoma of the thyroid is usually made in the process of investigating a thyroid nodule with clinical examination, Technetium-99m scan, ultrasonography and fine-needle aspiration (FNA) cytology. The follow-up is mainly based on 123-iodine and 131-iodine scans and serum thyroglogulin measurement. The aim of the present review was to establish the role of 18F-FDG PET in the differential diagnosis of doubtful thyroid nodules and in the follow-up of patients with increased serum thyroglobulin levels and negative iodine-scan. It remains to be defined if metabolic imaging with PET could be a useful routine procedure in the management of thyroid tumours since the majority of them are well-differentiated and therefore have less avidity to 18F-FDG. In the present work we collected the specific literature derived from MEDLINE over the last 10 years to clarify the potential clinical value of 18F-FDG PET in thyroid malignancies. An emerging role for 18F-FDG PET is in the assessment of incidental finding of a thyroid nodule which, when showing high FDG uptake should be regarded as a possible malignancy that needs further assessment. Another well-documented role for 18F-FDG PET is in the investigation of cases of established well-differentiated thyroid carcinomas presenting with high thyroglobulin and negative iodine imaging. An increase of the 18F-FDG uptake in these tumours indicates a shift towards lesser differentiation (with more aggression and poor prognosis) and may benefit from alternative management. 18F-FDG PET can be considered a routine functional imaging method in detecting iodine-negative recurrent disease in thyroid cancer patients with elevated serum thyroglobulin levels during follow-up. 18F-FDG PET seems to be useful also in differential diagnosis of suspected thyroid nodules, especially using the semi-quantitative SUV analysis.


    • 4 April 2008
      • Vol. 33  (2) , 39-40

    Nuclear medicine in endocrinology.

    by A Al-Nahhas, D Rubello